









시장가
/
주식
/
nasdaq-telo
/

Telomir Pharmaceuticals Inc

TELO

1.845USD

+0.085+4.83%

시장 운영 시간 （ET）시세는 15분 지연됩니다

54.91M시가총액

손실P/E TTM



Telomir Pharmaceuticals Inc

1.845

+0.085+4.83%

개요 회사 금융

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.

회사 정보

종목 코드 TELO

회사 이름Telomir Pharmaceuticals Inc

상장일Feb 09, 2024

CEOMr. Erez Aminov

직원 수- -

유형Ordinary Share

회계 연도 종료Feb 09

주소900 West Platt Street, Suite 200

도시TAMPA

증권 거래소NASDAQ Capital Market Consolidated

국가United States of America

우편 번호33606

전화18138642562

웹사이트https://telomirpharma.com/

종목 코드 TELO

상장일Feb 09, 2024

CEOMr. Erez Aminov

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Erez Aminov

Chairman of the Board, Chief Executive Officer

1.01M

+3288.20%

Mr. Craig Eagle, M.D.

Independent Director

487.81K

Dr. Matthew P. Del Giudice

Director

Mr. Ned Macpherson

Director

Mr. Matthew Pratt Whalen, CPA

Director

Mr. Alan Weichselbaum

Chief Financial Officer

이름

이름/직위

직위

주식 보유

변동

Mr. Erez Aminov

Chairman of the Board, Chief Executive Officer

1.01M

+3288.20%

Mr. Craig Eagle, M.D.

Independent Director

487.81K

Dr. Matthew P. Del Giudice

Director

Mr. Ned Macpherson

Director

Mr. Matthew Pratt Whalen, CPA

Director

Mr. Alan Weichselbaum

Chief Financial Officer

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Fri, May 16

주주

주주 유형

주주

비율

Bay Shore Trust

22.62%

McNulty (Brian Patrick)

6.31%

The Vanguard Group, Inc.

4.23%

BlackRock Institutional Trust Company, N.A.

3.76%

Aminov (Erez)

3.39%

Other

59.69%

주주

비율

Bay Shore Trust

22.62%

McNulty (Brian Patrick)

6.31%

The Vanguard Group, Inc.

4.23%

BlackRock Institutional Trust Company, N.A.

3.76%

Aminov (Erez)

3.39%

Other

59.69%

주주 유형

주주

비율

Corporation

22.62%

Individual Investor

11.55%

Investment Advisor

9.09%

Investment Advisor/Hedge Fund

2.98%

Research Firm

0.29%

Pension Fund

0.07%

Bank and Trust

0.07%

Other

53.33%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

13.89M

46.68%

+947.95K

2025Q1

13.90M

46.70%

+955.11K

2024Q4

13.75M

46.22%

+2.38M

2024Q3

14.68M

49.58%

+3.19M

2024Q2

12.97M

43.79%

+1.79M

2024Q1

12.67M

42.78%

+1.58M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Bay Shore Trust

6.73M

22.62%

-89.00K

-1.30%

Dec 31, 2024

McNulty (Brian Patrick)

1.88M

6.31%

-49.00K

-2.54%

Dec 31, 2024

The Vanguard Group, Inc.

1.26M

4.23%

-10.56K

-0.83%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

1.12M

3.76%

+119.04K

+11.91%

Mar 31, 2025

Aminov (Erez)

1.01M

3.39%

+979.88K

+3288.20%

Dec 31, 2024

Eagle (Craig)

487.81K

1.64%

Dec 31, 2024

Geode Capital Management, L.L.C.

429.25K

1.44%

+15.57K

+3.77%

Mar 31, 2025

Northern Trust Investments, Inc.

151.10K

0.51%

-525.00

-0.35%

Mar 31, 2025

State Street Global Advisors (US)

125.67K

0.42%

+9.88K

+8.53%

Mar 31, 2025

Suncoast Equity Management, LLC.

51.19K

0.17%

Mar 31, 2025